Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* 18 years and older~* Biopsy-proved cervical cancer or endometrial cancer within three months of study enrollment~* Standard-of-care (SOC) FDG PET/CT exam performed within 30 days of study enrollment~Exclusion Criteria:~* Female \< 18 years old~* No history of cervical cancer or endometrial cancer~* Primary biopsy \> 3 months of study enrollment~* Systemic therapy or radiation therapy initiated~* SOC FDG PET/CT exam performed \> 30 days of study enrollment~* Therapeutic procedures (chemotherapy, radiation therapy) have been initiated~* Pregnancy or lactation~* Claustrophobia or inability to tolerate the imaging procedure on the PET/MR scanner~* Individual is not willing to give informed consent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 18F fluciclovine PET scan (Type: EXPERIMENTAL): Subjects with recently biopsy-proven malignancy of the cervix or uterus undergo an 18F fluciclovine PET scan on a hybrid PET/MRI scanner after they have completed a standard-of-care F-18 FDG PET/CT study.

Based on this trial design, predict the completion outcome and termination type (if applicable).